deltatrials
Completed PHASE3 NCT00000589

Trial to Reduce Alloimmunization to Platelets (TRAP)

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Conditions Blood Platelets Blood Transfusion Hematologic Diseases Immunization Leukemia, Myelocytic, Acute
Interventions platelet transfusion
Updated 5 times since 2017 Last updated: Nov 4, 2016 Started: Aug 31, 1989 Completion: Jul 31, 1997

A PHASE3 clinical study on Blood Platelets and Blood Transfusion, this trial is completed. The trial is conducted by National Heart, Lung, and Blood Institute (NHLBI) and has accumulated 5 data snapshots since 1989. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Aug 1989

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Heart, Lung, and Blood Institute (NHLBI)
Data source: National Heart, Lung, and Blood Institute (NHLBI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.